AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Investigating Safety, Tolerability, Efficacy and PK of Olaparib in Paediatric Patients With Solid Tumours
- First Posted Date
- 2020-01-22
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 16
- Registration Number
- NCT04236414
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
A Study to Assess the Effect AZD4831 in Japanese and Chinese Healthy Volunteers
Phase 1
Completed
- Conditions
- Heart Failure With Preserved Ejection Fraction (HFpEF)
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2021-04-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 32
- Registration Number
- NCT04232345
- Locations
- 🇺🇸
Research Site, Glendale, California, United States
Characterizing the Cross-sectional Approach to Investigate the Prevalence of Tissue BRCA1/2 Mutations in Newly Diagnosed Advanced Ovarian Cancer Patients
Completed
- Conditions
- Ovarian Neoplasms
- First Posted Date
- 2020-01-10
- Last Posted Date
- 2021-10-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 207
- Registration Number
- NCT04222465
- Locations
- 🇯🇵
Research Site, Yamagata, Japan
Patient-reported Outcomes in Real-world Use of Benralizumab in Patients With Severe Eosinophilic Asthma in Belgium
Completed
- Conditions
- Severe Asthma
- First Posted Date
- 2020-01-09
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 76
- Registration Number
- NCT04221802
- Locations
- 🇧🇪
Research Site, Roeselare, Belgium
Reduce Incidence of Pre-Dialysis Hyperkalaemia With Sodium Zirconium Cyclosilicate in Chinese Subjects
Phase 3
Completed
- Conditions
- Hyperkalemia
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-01-03
- Last Posted Date
- 2023-03-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 134
- Registration Number
- NCT04217590
- Locations
- 🇨🇳
Research Site, Yinchuan, China
A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer
Phase 2
Active, not recruiting
- Conditions
- Advanced ER-Positive HER2-Negative Breast Cancer
- Interventions
- First Posted Date
- 2020-01-02
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 240
- Registration Number
- NCT04214288
- Locations
- 🇬🇧
Research Site, Leicester, United Kingdom
A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors
Phase 1
Terminated
- Conditions
- Advanced Solid TumorsMultiple MyelomaLymphomaHematologic Malignancies
- Interventions
- First Posted Date
- 2019-12-30
- Last Posted Date
- 2023-08-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 9
- Registration Number
- NCT04214093
- Locations
- 🇺🇸
Research Site, Houston, Texas, United States
Efficacy and Safety of MEDI3506 in Adult Subjects With Atopic Dermatitis
- First Posted Date
- 2019-12-26
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 148
- Registration Number
- NCT04212169
- Locations
- 🇬🇧
Research Site, Wokingham, United Kingdom
A Study to Assess the Amount of Drug Levels in Blood and Safety of AZD5718 Formulations in Healthy Volunteers
Phase 1
Completed
- Conditions
- Coronary Artery Disease (CAD)
- Interventions
- Drug: AZD5718 tablet, Formulation DDrug: AZD5718 tablet, Formulation ADrug: AZD5718 film-coated tablet, Reference treatmentDrug: AZD5718 tablet, Formulation BDrug: AZD5718 tablet, Formulation C
- First Posted Date
- 2019-12-24
- Last Posted Date
- 2020-03-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 12
- Registration Number
- NCT04210388
- Locations
- 🇬🇧
Research Site, Harrow, United Kingdom
Safety and Tolerability Study of Cotadutide in Japanese Obese Subjects With Type 2 Diabetes Melitus
- First Posted Date
- 2019-12-23
- Last Posted Date
- 2020-07-31
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 16
- Registration Number
- NCT04208620
- Locations
- 🇯🇵
Research Site, Suita-shi, Japan
© Copyright 2025. All Rights Reserved by MedPath